SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.
March 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Businessman receiving large stacks of money from a giant hand. Concept of funding, venture capital, financial support, dividend, and profitable business.
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
The funding comes weeks after TL1A blocker duvakitug maintained clinical remission rates above 50% in patients with ulcerative colitis and Crohn’s disease in a Phase 2b trial.
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
While an anonymous source tied the closure to shortcomings in the FDA’s new pathway, a spokesperson for the Department of Health and Human Services pushed back on the suggestion.
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Composite contemporary collage statue of justice themis femida on the background of the target as the concept and idea of justice and law. High quality photo
Patents
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant
The settlement, which requires Moderna to pay the plaintiffs $950 million upfront plus up to $1.3 billion in contingent commitments, is an outcome “better than feared,” according to analysts.
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Reaching an agreement. Businessmen shake hands and make a deal. vector
Immunology and inflammation
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals
Sanofi will gain global exclusive rights over rovadicitinib, an oral JAK/ROCK blocker that has anti-inflammatory and anti-fibrotic effects.
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
cloud with rain of coins on blue background. minimal concept of investment, success and cryptocurrencies. 3d rendering
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter,” early stage biotechs are rewriting their financing strategies around nondilutive capital and targeted private wealth.
March 4, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Illustration showing businessperson looking through telescope at potential growth
Job Trends
The Job Market May Be Warming—What Does That Mean for You?
Employees are reassessing, leaders are celebrating data that should make them nervous and job seekers are absorbing a narrative that doesn’t match their reality. Executive coach Angela Justice discusses how each of these groups are affected when the job market thaws.
March 4, 2026
 · 
4 min read
 · 
Angela Justice
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Earnings
Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.
March 4, 2026
 · 
9 min read
 · 
Tristan Manalac
Person jumping to arrow with another direction, in vintage colors stock illustration
Venture capital
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.
March 3, 2026
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS